These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9354768)

  • 1. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
    Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
    Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
    Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
    Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies.
    Perfetti V; Bellotti V; Garini P; Zorzoli I; Rovati B; Marinone MG; Ippoliti G; Merlini G
    Lab Invest; 1994 Dec; 71(6):853-61. PubMed ID: 7807967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
    Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
    Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.
    Pilarski LM; Jensen GS
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):297-322. PubMed ID: 1533857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
    Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
    Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive endocytosis and degradation of CD22 by human B cells.
    Shan D; Press OW
    J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of myeloma cells in the peripheral blood by flow cytometry.
    Witzig TE; Kimlinger TK; Ahmann GJ; Katzmann JA; Greipp PR
    Cytometry; 1996 Jun; 26(2):113-20. PubMed ID: 8817086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD22 as a target of passive immunotherapy.
    Cesano A; Gayko U
    Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.
    Viemann D; Schlenke P; Hammers HJ; Kirchner H; Kruse A
    Eur J Immunol; 2000 Feb; 30(2):550-9. PubMed ID: 10671211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
    Nguyen DH; Ball ED; Varki A
    Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
    Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different expression of CD3 and CD22 in leukemic cells according to whether tested in suspension or fixed on slides.
    Rani S; De Oliveira MS; Catovsky D
    Hematol Pathol; 1988; 2(2):73-8. PubMed ID: 2974027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLP-76 is recruited to CD22 and dephosphorylated by SHP-1, thereby regulating B cell receptor-induced c-Jun N-terminal kinase activation.
    Mizuno K; Tagawa Y; Watanabe N; Ogimoto M; Yakura H
    Eur J Immunol; 2005 Feb; 35(2):644-54. PubMed ID: 15668918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.